Ovarian cancer is one of the most leading fetal gynaecological
malignancies in women worldwide . The high mortality rate of
this disease is because of its poor prognosis and that approximately
75% of the patients are diagnosed at advanced stages (FIGO stages
III and IV). Therefore, adjuvant chemotherapy is necessary for the
clinical management of patients with advanced tumors . Platinumbased
combination chemotherapy is the standard first-line strategy
for ovarian cancer patients. Although initial treatment achieves high
percentage in responses, most of the patients will eventually develop
resistance to anti-cancer drugs . Therefore, chemoresistance
is the major clinical obstacle for the treatment of ovarian cancer
patients nowadays. Mounting evidences have documented that de
novo (intrinsic) and acquired (extrinsic) chemoresistance are two
major most likely mechanisms in various human cancers. However,
the precise mechanism for chemoresistance in ovarian cancer remains
unclear. (Liu MX, Chan DW, Ngan HYS (2012) Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance.)
Last date updated on September, 2024
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi